Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2025 | Story Tshepo Tsotetsi | Photo Stephen Collett
Moot Court
The Law Clinic in the Faculty of Law at the University of the Free State (UFS) hosted the 20th annual Kovsie Moot Court Competition from 4 to 6 August 2025.

The Law Clinic in the Faculty of Law at the University of the Free State (UFS) recently hosted the 20th annual Kovsie Moot Court Competition, which brings together first-year law students from across Southern Africa. The competition took place from 4 to 6 August 2025 at the Supreme Court of Appeal (SCA) in Bloemfontein, offering students the rare opportunity to present arguments in one of the country’s highest courts.

Participating institutions included Eduvos (Bloemfontein Campus), the University of Johannesburg, Rhodes University, and the National University of Lesotho, among others. 

 

Moot Court as a culture and a foundation

Pinky Mokemane, Moot Court Coordinator at UFS, described the competition as far more than an event. “Moot Court is a culture. It brings to life everything students have been studying. They are not just reading theory – they are applying it, speaking it, and defending it,” she said.

Over 200 first-year LLB students signed up to participate in this year’s internal selection process, and three – Niniwe Rens, Kabelo Mokhotla, and Sfiso Mbasela – were ultimately selected to represent UFS. Mokemane said being able to argue legal points in the SCA is a privilege no other university currently offers, and students should not take this opportunity for granted.

Legal Behemoth, a UFS student association that works closely with the Law Clinic to promote a strong moot culture at the university, was a critical force behind the success of this year’s Moot Court programme. The group plays a central role in planning the competition – training students, liaising with legal professionals, and teaching foundational advocacy skills from scratch.

Lethabo Lekhuleng, Chairperson of Legal Behemoth, explained that the group’s support starts long before the competition itself. “We begin by training the students from the ground up. Most of them don’t know anything about oral advocacy or courtroom procedure. So we guide them, give direction, and help them build confidence step by step,” she said.

Describing the students’ growth over the course of the competition, she added, “It was definitely the confidence [that grew]. From the first round to the final round, they became far surer of themselves in how they spoke, how they presented arguments, and how they carried themselves in court.”

Herman du Randt, a senior associate at PH Attorneys and a UFS alumnus, was one of the judges presiding over the competition. “We were looking for confidence. A student must show that they trust themselves and know their arguments. It is not only what you say, but why you say it, and the legal authority behind it,” he explained. 

Du Randt was deeply impressed, describing the students’ overall performance as “breathtaking”. “The amount of effort they put in, the depth of their research, and the clarity of their arguments was exceptional,” he said.

He also emphasised the importance of such competitions in shaping the future of legal professionals. Drawing from his experience of representing UFS internationally through Moot Court, he said, “There are thousands of students graduating with LLBs every year. You need something that makes you stand out. Moot Court is one of the most exposure-rich things you can do as a student. If you don’t take part, you miss a huge opportunity.”

 

Growth through experience: voices from the court floor

Rens and Mokhotla spoke candidly about their experience. “It was hectic. There were sleepless nights, a lot of preparation. But it was all worth it,” Rens said. Both students want to become advocates, and for them, presenting arguments in the SCA was a glimpse into their future.

Mokhotla reflected on what the experience taught her about herself: “I am not defined by failure. The fact that I stood in that court and saw my name there already meant so much. It was nerve-wracking, but I pushed myself to the limit – and that’s what I’ll take with me.”

Christopher Rawson, Acting Director of the UFS Legal Clinic, placed this year’s Moot Court effort within a broader educational vision. “The UFS Law Clinic plays a unique role in integrating practical legal education into the formal curriculum. The clinic hosts the competition and facilitates access to real-world and professionally relevant experiences in a court that is steeped in constitutional history, intellectual rigour, and the pursuit of justice. By doing so, the competition also supports the UFS’s Vision 130 commitments to producing graduates who are socially engaged, ethically grounded, and professionally competent,” he said.

Rawson also noted that early exposure to legal reasoning and oral argument builds the analytical and ethical foundation that students need. “From their initial submissions to their final oral arguments, the growth shown by our students reflects the strength of our approach – combining academic knowledge with skills-based learning and mentorship.”

Through its 20th edition, the Kovsie Moot Court Competition once again demonstrated that legal education at UFS is not confined to lecture halls. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept